AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

User:

Stage 1: History of Biphasic Relapsing Cytopenias & Tick-Exposed Outdoor Lifestyle (Timestamp: 2 Weeks Prior to Admission)
A 30-year-old man (residing in Delhi NCR, restaurant cook / outdoorsman, history of alcohol-use disorder, peptic ulcer disease, Barrett's esophagus, anxiety) presents with a 2-week history of fatigue, exertional dyspnea, high fevers, night sweats, skin rash, and dark urine.
HPI:
- 3 Years Ago (Episode 1): Motor vehicle accident causing abdominal wall hematomas. 2 days later, developed acute severe thrombocytopenia (platelets 22,000/µL, down from 193,000/µL overnight!), moderate anemia (Hb 13.0 g/dL), and gross hematuria. Recovered spontaneously without plasma exchange and remained healthy for 3 years!
- Current Episode: 2 weeks of fatigue and panic-like palpitations; 5 days of high fevers (38.3°C) and night sweats; 3 days of an erythematous rash on the right knee and arm bruising. Removed a tick 2 weeks prior. Prescribed Doxycycline + Clindamycin + Quinine after Lyme serology screening was positive.

Resident:

Hello, Chief Resident here.

Key Findings:
* Tick exposure with rash, fevers, night sweats, cytopenias (bruising, fatigue), and dark urine.
* Biphasic course: Acute severe drop in platelets/hemoglobin with dark urine 3 years prior (post-trauma), now relapsing.
* Positive Lyme serology; empirically started on Doxycycline/Clindamycin/Quinine.

Differential Diagnoses:
1. Babesiosis (± Lyme Co-infection) – 45%: Dark urine indicates intravascular hemolysis; key cause of tick-borne cytopenias.
2. Anaplasmosis / Ehrlichiosis – 25%: High fevers, marked cytopenias, tick vector; rash less common but possible.
3. Infection-Triggered TMA / Relapsing TTP – 15%: Explains sudden severe platelet drops, hemolysis, dark urine, and past episodic recurrence.
4. Relapsing Fever Borreliosis – 15%: Biphasic fevers, cytopenias, rash, and endemic exposure history.

Recommended Prioritized Tests:
1. Peripheral Blood Smear: Look for Babesia ring forms/Maltese cross, Anaplasma morulae, or schistocytes.
2. Tick-Borne Pathogen PCR Panel: Direct detection of Babesia, Anaplasma, Ehrlichia, and Borrelia DNA.
3. Hemolysis Workup: LDH, haptoglobin, indirect bilirubin, reticulocytes, direct Coombs test, and urine hemoglobin.
4. ADAMTS13 Activity Assay: Rule out acquired/congenital TTP given the biphasic hematologic drops.
5. Repeat CBC with Differential: Track severity of cytopenias.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of smear/PCR/hemolysis labs, but underweights non-infectious mimics given biphasic post-trauma cytopenias + dark urine; empiric quinine risks cinchonism without confirmed Babesia; Lyme serology alone insufficient in endemic/non-endemic overlap (Delhi NCR). Add G6PD before quinine and hold plasma exchange pending ADAMTS13.

Top 3 DDx:
1. Babesiosis (tick + intravascular hemolysis + biphasic cytopenias)
2. Relapsing TTP/TMA (trauma-triggered sentinel episode, spontaneous recovery)
3. Anaplasmosis with secondary HLH-like features

Specific points:
1. Urgent smear for intraerythrocytic parasites/schistocytes before further abx.
2. Pair Babesia PCR with thick/thin films + IgM/IgG.
3. Full TMA panel: ADAMTS13, complement, homocysteine.
4. G6PD assay pre-quinine; switch to atovaquone-azithromycin if G6PD-def.
5. Quantify alcohol/PUD contribution to anemia (endoscopy if stable).
6. Repeat tick-borne serologies + blood cultures for Borrelia miyamotoi.
7. Hold clindamycin/quinine pending confirmatory parasitology.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: tick-borne Babesia infection causing intravascular hemolysis/cytopenias, possibly unmasking relapsing TMA/PNH. Fits: tick, fevers/sweats, bruising, dark urine; prior abrupt platelet crash after trauma may be a first complement/ADAMTS13 or PNH flare. Against pure babesiosis: Delhi NCR makes Lyme serology likely false-positive/cross-reactive; Babesia must be proven before quinine. Differentials: anaplasma/ehrlichia/rickettsiosis—fits tick, fever, cytopenias, but dark urine less typical; relapsing TTP/atypical HUS—fits biphasic thrombocytopenia/hemolysis and triggers, but spontaneous recovery argues for an infection trigger; PNH—fits dark urine/relapsing hemolysis, less the tick rash. Key pivot: prove whether urine is hemoglobin from parasites/PNH versus schistocyte TMA. Next move: urgent thick/thin smear, Babesia PCR, CBC/retic/LDH/haptoglobin/bilirubin/Coombs/urinalysis, ADAMTS13, complement and PNH flow cytometry, G6PD before quinine; continue doxycycline while confirming, PLEX only if severe ADAMTS13 deficiency/MAHA. Pearl: serology is a clue; smear plus hemolysis phenotype is the diagnosis.

Round 2

User:

Stage 2: Physical Exam & Severe Coombs-Negative MAHA with Severe Thrombocytopenia (Timestamp: Admission / Day 1)
Physical Exam: Temp 36.6°C, HR 88 bpm, BP 112/57 mmHg, RR 18/min, SpO2 99% on room air. Alert, oriented. Abdomen soft, non-tender, no hepatosplenomegaly. Skin: 6-cm blanching erythematous plaque in right popliteal fossa (erythema migrans) and 5-cm erythematous plaque near left patella with petechiae on left flank and arms.
Initial Laboratory Workup:
- CBC & Smear: WBC 9,000/µL (63% neutrophils, 5% bands, 5% metamyelocytes), Hemoglobin 5.8 g/dL (Hct 17.6%, MCV 94 fL), Platelets 15,000/µL (severe thrombocytopenia!). Reticulocytes 16.2% (marked reticulocytosis!). Smear: Occasional schistocytes (<1/hpf, rising to 2-3/hpf), no intraerythrocytic Babesia parasites.
- Chemistry & Urinalysis: Total Bilirubin 1.4 mg/dL, LDH 1,122 U/L, Haptoglobin UNDETECTABLE (<6 mg/dL), Ferritin 1,161 µg/L, D-Dimer 3,043 ng/mL. Creatinine 1.01 mg/dL (normal!). Fibrinogen 441 mg/dL, PT 13.4s (INR 1.1), aPTT 28.9s (normal PT/aPTT, ruling out DIC!). Direct Coombs test negative. Urinalysis: 2+ blood, 2+ protein, 20–50 RBCs/hpf.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Severe Coombs-negative MAHA (Hb 5.8 g/dL, LDH 1,122 U/L, haptoglobin <6, schistocytes) and severe thrombocytopenia (15,000/µL).
* Classic Erythema Migrans rash with normal renal function and normal PT/aPTT/fibrinogen (DIC excluded).

Differential Diagnoses:
1. Infection-Triggered TTP / TMA (50%): Extreme thrombocytopenia and MAHA with preserved renal function strongly suggest TTP, likely triggered by a tick-borne pathogen or prior trauma.
2. Anaplasmosis / Lyme Co-infection with Microangiopathic Cytopenias (25%): Confirmed EM rash; acute tick-borne illness driving secondary platelet/RBC destruction.
3. Complement-Mediated TMA (aHUS) (15%): Explains biphasic, trigger-happy (trauma, infection) Coombs-negative MAHA and thrombocytopenia.
4. Paroxysmal Nocturnal Hemoglobinuria (PNH) (10%): Biphasic intravascular hemolysis and cytopenias unmasked by acute infection.

Recommended Prioritized Tests:
1. STAT ADAMTS13 Activity & Inhibitor Screen: Critical to confirm TTP (<10% activity) and initiate plasma exchange (PLEX).
2. PNH Flow Cytometry (CD55/CD59): Rule out PNH clone.
3. Tick-Borne Pathogen PCR Panel: Direct detection of Borrelia, Anaplasma, Ehrlichia.
4. Complement Functional & Genetic Panel: Evaluate for alternative pathway dysregulation (aHUS).
5. G6PD Enzymatic Assay: Assess risk prior to oxidant antimicrobial therapies.

Attending:

Hello Attending Consultant here

Critique: Overweights primary TTP given few schistocytes, preserved Cr, and clear EM; under-emphasizes smear-negative babesiosis (common early) and infection-driven secondary TMA. ADAMTS13 STAT is correct but pair with immediate empiric atovaquone-azithro while holding quinine; PLEX only if ADAMTS13 <10% + progressive MAHA.

Top 3 DDx:
1. Babesiosis ± Lyme (EM + intravascular hemolysis + TCP; smear can be negative)
2. Infection-triggered TTP/TMA (biphasic, trauma/tick triggers)
3. Anaplasmosis with secondary MAHA

Specific points:
1. Repeat thick/thin smears q12h + Babesia PCR/bloods.
2. Start atovaquone + azithromycin now; doxycycline for EM/Anaplasma coverage.
3. ADAMTS13 + inhibitor STAT; prepare but defer PLEX.
4. PNH flow + complement panel (C3/C4/AH50/genetic).
5. Transfuse RBCs/platelets judiciously; monitor for cardiac ischemia.
6. Serial LDH/haptoglobin/schistocyte counts + retic.
7. Hold quinine pending G6PD and parasitology confirmation.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis now: babesiosis (smear-negative early), with Lyme EM and Coombs-negative intravascular hemolysis causing secondary TMA; tick-borne anaplasma is a close co-player. Fits: EM plaques, febrile sweats, haptoglobin zero, LDH high, urine heme-positive with RBCs, biphasic relapses. Less fitting: classic TTP usually has more schistocytes, neuro/renal change, and platelets this low can occur in babesiosis; aHUS/PNH can relapse with infection but EM is decisive for tick illness. DIC essentially excluded. Key pivot: separate parasite-driven hemolysis from ADAMTS13-deficient TMA before committing to PLEX. Next move: STAT ADAMTS13 activity/inhibitor, repeat thick/thin smears q12h plus Babesia microti/divergens PCR, Anaplasma/Ehrlichia/Borrelia PCR, PNH flow, complement C3/C4/AH50, G6PD; transfuse to symptomatic thresholds, monitor QT/hemolysis. Treat empirically for babesiosis/EM/anaplasma while results pend; reserve PLEX for ADAMTS13 <10% or worsening MAHA/neuro. Pearl: normal creatinine does not exclude babesiosis, and a negative first smear never rules it out.

Round 3

User:

Stage 3: Acute Neurologic Deficit & High-Risk PLASMIC Score (6/7) (Timestamp: Hospital Day 3)
Hospital Day 3 Event: Sudden onset of expressive aphasia, pronator drift of the right arm, and inability to follow complex commands (focal cerebral microthrombosis / transient ischemic attack!).
Neuroimaging: Emergency CT Angiography of head/neck revealed normal intracranial vessels without acute stroke or hemorrhage.
PLASMIC Risk Stratification:
- Severe thrombocytopenia (<30k): YES (+1)
- Hemolysis (Reticulocytes >2.5%, Haptoglobin <6): YES (+1)
- No active cancer: YES (+1)
- No transplant history: YES (+1)
- MCV <90 fL: NO (94 fL, 0)
- INR <1.5: YES (+1)
- Creatinine <2.0 mg/dL: YES (+1)
- Total PLASMIC Score = 6/7 (High Risk of Severe ADAMTS13 Deficiency <10%!).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* New focal neurological deficits (expressive aphasia, right arm drift) indicating cerebral microvascular ischemia.
* High PLASMIC score (6/7) strongly predicting severe ADAMTS13 deficiency (<10%).
* Progression to classic TTP pentad (MAHA, severe thrombocytopenia, fever, neurological signs) triggered by tick-borne exposure.

Differential Diagnoses:
1. Thrombotic Thrombocytopenic Purpura (TTP - Infection/Tick-Triggered) – 75%: Acute neurologic compromise plus PLASMIC score 6/7 makes TTP the top, life-threatening diagnosis.
2. Severe Babesiosis / Anaplasmosis with Secondary TMA – 15%: Direct pathogen-driven endothelial damage and microvascular occlusion.
3. Complement-Mediated TMA (aHUS) – 10%: Infection-triggered alternative pathway dysregulation with extra-renal (neurologic) involvement.

Recommended Prioritized Actions & Tests:
1. Immediate Therapeutic Plasma Exchange (PLEX) + Corticosteroids (± Caplacizumab): Emergent initiation required; do not delay treatment while awaiting lab confirmation.
2. Brain MRI (DWI/FLAIR): Detect subtle microinfarcts or focal ischemia not visualized on CT.
3. Expedite ADAMTS13 Activity & Inhibitor Levels: Definitive diagnostic confirmation.
4. STAT Babesia & Anaplasma PCR: Rule out active infection driving or compounding the TMA.
5. Neuro-ICU Transfer: Intensive monitoring for progressive neurological decline or organ dysfunction.

Attending:

Hello Attending Consultant here

Critique: Correctly escalates to empiric PLEX given PLASMIC 6/7 + focal neuro deficits, but over-commits to primary TTP (75%) while underweighting smear-negative babesiosis as TMA trigger; neuro events occur in both. Do not drop dual antimicrobial coverage or PNH/complement labs. Caplacizumab only post-ADAMTS13 confirmation.

Top 3 DDx:
1. Infection-triggered TTP (PLASMIC 6/7 + cerebral microthrombosis)
2. Severe babesiosis ± Lyme with secondary TMA
3. Anaplasmosis-driven TMA / aHUS overlap

Specific points:
1. Initiate PLEX + steroids immediately; add caplacizumab only if ADAMTS13 <10%.
2. Continue atovaquone-azithromycin + doxycycline through PLEX.
3. STAT ADAMTS13 activity/inhibitor + serial smears/Babesia PCR.
4. Urgent MRI brain (DWI) for microinfarct burden.
5. PNH flow cytometry + complement panel (C3/C4/AH50).
6. Neuro-ICU monitoring; avoid platelet transfusion unless life-threatening bleed.
7. Daily LDH/platelets/schistocytes to gauge PLEX response.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: acquired TTP with cerebral microthrombosis, plausibly triggered by tick-borne infection—especially babesiosis with Lyme/anaplasma co-exposure. The expressive aphasia and pronator drift with normal CTA fit microvascular TTP rather than large-vessel stroke. PLASMIC 6/7 makes severe ADAMTS13 deficiency likely, but it does not exclude infection-driven secondary TMA.

Differentials: severe babesiosis remains important because hemolysis, thrombocytopenia, fevers, and negative early smears fit; anaplasma/ehrlichia fits cytopenias and tick exposure but less well the MAHA; aHUS/PNH could relapse after infection, yet the neurologic event plus PLASMIC profile favors TTP.

Key pivot: new focal neurology converts this from “possible TMA” to a treat-first emergency.

Next move: obtain ADAMTS13 activity/inhibitor immediately, but start plasma exchange and corticosteroids without waiting; add caplacizumab once severe deficiency is confirmed. Continue tick-borne evaluation and empiric coverage, repeat smears/PCR, MRI-DWI, PNH flow, and complement studies. Avoid platelet transfusion unless life-threatening bleeding.

Pearl: in suspected TTP, neurologic change is the point where diagnostic certainty must never delay plasma exchange.

Round 4

User:

Stage 4: ADAMTS13 Biomarker Paradox & Genetic Sequencing (Timestamp: Hospital Days 4-6)
Emergency Intervention & Biomarker Paradox:
- Emergency Intervention: Daily Therapeutic Plasma Exchange (TPE) + IV Glucocorticoids initiated immediately. Aphasia and headache resolved after 1st/2nd TPE; platelets normalized after 3rd session. TPE stopped on Day 6 (ADAMTS13 activity recovered to 62%).
- Diagnostic Biomarker Discrepancy:
- ADAMTS13 Activity: <5% (severely deficient, confirming TTP!).
- ADAMTS13 Neutralizing Inhibitor Assay: <0.4 inhibitor units (NEGATIVE!).
- Anti-ADAMTS13 IgG Autoantibody ELISA: 56 arbitrary units (POSITIVE!).
Genetic Sequencing: Identified compound heterozygous pathogenic sequence variants in the ADAMTS13 gene (c.98delT [exon 1] and c.3178C->T [exon 24]), confirming underlying autosomal recessive inherited TTP.
Unifying Diagnosis: Combined Inherited (Upshaw-Schulman Syndrome) and Acquired Thrombotic Thrombocytopenic Purpura (TTP) — baseline partial congenital ADAMTS13 deficiency triggered into acute microvascular thrombosis by physiological stress (trauma 3 years prior) and tickborne infection (B. burgdorferi).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Severely deficient ADAMTS13 activity (<5%) with positive IgG autoantibodies.
* Genetic sequencing confirms compound heterozygous pathogenic ADAMTS13 variants (c.98delT / c.3178C->T).
* Rapid complete clinical/hematologic recovery post-TPE, confirming Upshaw-Schulman Syndrome (USS) unmasked by a secondary autoimmune flare and Borrelia burgdorferi infection.

Differential Diagnoses:
1. Congenital TTP (Upshaw-Schulman Syndrome) with Acquired Autoantibody Overlap & Tick Trigger – 85%: Confirmed by genetics; unifies the post-trauma sentinel episode and current tick-borne flare.
2. Primary Acquired Autoimmune TTP – 10%: Driven by IgG autoantibodies, though presence of dual pathogenic mutations overwhelmingly indicates underlying USS.
3. Infection-Induced Secondary TMA / aHUS Overlap – 5%: Excluded as primary driver given severe ADAMTS13 deficiency (<5%) and genetic diagnosis.

Recommended Next Steps:
1. Genetic Counseling & Cascade Screening: Evaluate first-degree relatives for ADAMTS13 mutations.
2. Long-Term Prophylaxis Planning: Evaluate for recombinant ADAMTS13 (Adzynma) or regular plasma infusions during high-risk stressors (infections, procedures).
3. Serial Biomarker Surveillance: Monitor ADAMTS13 activity and IgG autoantibody titers periodically.
4. Complete Antimicrobial Therapy: Ensure full eradication of Borrelia and tick-borne co-pathogens.
5. Patient Education: Issue medical alert branding and strict avoidance of unmonitored triggers.

Attending:

Hello Attending Consultant here

Critique: Excellent integration of genetics confirming USS, but overstates "acquired autoantibody overlap" as primary driver—negative functional inhibitor with positive ELISA IgG suggests non-neutralizing Abs or assay artifact, not classic iTTP. Under-emphasizes need to exclude ongoing infection as residual trigger; prophylaxis planning is premature without baseline ADAMTS13 kinetics post-recovery. Rapid TPE response fits congenital more than pure acquired.

Top 3 DDx:
1. Congenital TTP (USS) unmasked by Borrelia stressor (genetics + biphasic triggers)
2. Hybrid congenital/acquired TTP (low activity + ELISA+ IgG)
3. Infection-triggered secondary TMA on USS background

Specific points:
1. Repeat ADAMTS13 activity/inhibitor/ELISA off TPE to establish true baseline.
2. Full tick-borne PCR/serologies to confirm Borrelia clearance; complete doxy course.
3. Cascade family screening + genetic counseling for ADAMTS13 variants.
4. Consider recombinant ADAMTS13 prophylaxis only for high-risk periods (infection/surgery).
5. Serial monitoring: ADAMTS13 q3-6mo + education on trigger avoidance.
6. PNH/complement recheck if hemolysis recurs off therapy.
7. Avoid empiric caplacizumab given negative inhibitor.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: congenital TTP/Upshaw-Schulman syndrome with an acute flare triggered by physiologic stressors, most recently tick-borne infection. The biallelic pathogenic ADAMTS13 variants, prior trauma-provoked episode, severe deficiency, and rapid response to plasma replacement strongly fit.

The positive anti-ADAMTS13 IgG with a negative functional inhibitor should not be overcalled as acquired TTP; it may represent a non-neutralizing antibody or assay discordance. Acquired autoimmune TTP remains possible but is less supported. Infection-associated secondary TMA, atypical HUS, or PNH are much less likely given ADAMTS13 <5% and the genetic result.

Key pivot: the biomarker paradox—severe ADAMTS13 deficiency, negative inhibitor, positive ELISA, and compound heterozygous mutations—shifts the case from pure acquired TTP to inherited TTP with an environmental trigger.

Next move: repeat ADAMTS13 activity, inhibitor, and antibody testing after recovery/off TPE to establish baseline and antibody persistence; confirm tick-borne infection clearance, provide genetic counseling and family screening, and plan prophylactic ADAMTS13 replacement for future high-risk stressors.

Pearl: a positive antibody assay does not prove acquired TTP when functional inhibition is absent and pathogenic ADAMTS13 variants are present.

Round 5

User:

Stage 5: Early Relapse, Rituximab B-Cell Depletion & Long-Term FFP Prophylaxis (Timestamp: Follow-up & Discharge)
Early Relapse & Long-Term Management:
- Early Relapse Event: 14 Days post-TPE stop, platelet count dropped to 120,000/µL with ADAMTS13 activity falling again to <5%. Plasma infusions (without exchange) given for 3 days without platelet rise (confirming non-neutralizing clearance autoantibodies!). Single session of TPE boosted platelets to 200,000/µL.
- Long-Term Targeted Therapy & Prophylaxis:
- Initiated Rituximab 375 mg/m² weekly x 4 doses to clear the anti-ADAMTS13 IgG clearance autoantibodies, maintaining normal platelets and LDH.
- Established long-term prophylactic Fresh Frozen Plasma (FFP) infusions every 8 to 10 weeks (without exchange) to supply functional ADAMTS13 enzyme, preventing future stress-induced relapses.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Early relapse 14 days post-TPE (platelets 120,000/µL, ADAMTS13 <5%) refractory to simple FFP infusion, but responsive to TPE and Rituximab.
* Phenotype confirms non-neutralizing clearance autoantibodies accelerating enzyme destruction on a background of Upshaw-Schulman Syndrome (USS).

Differential Diagnoses:
1. Congenital TTP (USS) with Acquired Clearance Autoantibodies – 85%: Proven compound heterozygous variants (c.98delT/c.3178C->T) coupled with antibody-mediated clearance responsive to Rituximab.
2. Acquired Autoimmune TTP with Incidental ADAMTS13 Variants – 10%: Autoimmune behavior and relapse drive, though dual pathogenic mutations confirm inherited substrate.
3. Persistent Infection-Triggered Immune TMA – 5%: Unlikely primary cause following complete antimicrobial therapy and clear response to immunomodulation.

Recommended Next Steps:
1. Monitor ADAMTS13 & Peripheral B-Cells (CD19/CD20): Track autoantibody clearance and target B-cell depletion post-Rituximab.
2. Transition to Recombinant ADAMTS13 (Adzynma): Replace chronic FFP prophylaxis to minimize volume overload and transfusion-related risks.
3. Cascade Genetic Screening: Offer testing to first-degree relatives for the identified ADAMTS13 mutations.
4. Infection & Trigger Protocol: Provide emergency medical alert documentation and early-intervention protocols for future physiological triggers.

Attending:

Hello Attending Consultant here

Critique: Correctly identifies clearance Abs driving early relapse on USS substrate and endorses rituximab + FFP, but overcalls “non-neutralizing” without pharmacokinetic data; under-emphasizes need for post-ritux ADAMTS13 kinetics before locking FFP interval. rADAMTS13 transition is preferred over chronic FFP.

Top 3 DDx:
1. USS + acquired clearance autoantibodies (genetics + ELISA+ + FFP-refractory relapse)
2. Hybrid congenital/acquired TTP
3. Residual infection-triggered immune clearance on USS background

Specific points:
1. Serial ADAMTS13 activity/ELISA + CD19 counts q4–6 wk post-rituximab to confirm B-cell depletion and Ab clearance.
2. Switch to recombinant ADAMTS13 (Adzynma) prophylaxis; reserve FFP for breakthrough only.
3. Pharmacokinetic study (pre/post-infusion ADAMTS13 half-life) to prove accelerated clearance.
4. Cascade family screening + genetic counseling.
5. Re-check tick-borne PCR/serologies; complete any residual antimicrobial course.
6. Medical-alert + trigger-action plan (infection/surgery → immediate plasma/rADAMTS13).
7. Avoid empiric caplacizumab given negative functional inhibitor.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: congenital TTP/Upshaw-Schulman syndrome with superimposed acquired anti-ADAMTS13 clearance autoantibodies, initially unmasked by trauma and later tick-borne infection. This best explains biallelic pathogenic variants, recurrent stress-provoked severe deficiency, positive IgG, early post-TPE relapse, and response to exchange plus B-cell depletion.

Key differentials: acquired autoimmune TTP with incidental variants—possible but less likely; inadequate replacement or ongoing consumption rather than true antibody-mediated clearance—requires pharmacokinetic confirmation; persistent infection or complement-mediated TMA—unlikely given the ADAMTS13 pattern and treatment response.

Key pivot: failure of plasma infusion alone but rapid response to TPE, suggesting accelerated antibody-mediated clearance rather than simple enzyme deficiency.

Next move: serial platelet/LDH, ADAMTS13 activity, antibody level, and B-cell recovery after rituximab; perform pre/post-infusion ADAMTS13 recovery and half-life testing to individualize prophylaxis. Prefer recombinant ADAMTS13 prophylaxis where available, reserving plasma for breakthrough episodes. Confirm infection clearance, provide family genetic screening, and establish an early-treatment plan for infection, surgery, pregnancy, or trauma.

Pearl: a negative functional inhibitor does not exclude clinically important clearance antibodies; enzyme recovery and half-life are decisive.

Top 15 Takeaways for Clinicians

  1. Genetics of Congenital TTP (Upshaw-Schulman Syndrome): Inherited TTP is caused by autosomal recessive compound heterozygous or homozygous pathogenic mutations in the ADAMTS13 gene, resulting in persistent severe ADAMTS13 enzyme deficiency.
  2. Stress-Induced Microvascular Thrombosis Flares: Patients with partial congenital ADAMTS13 deficiency maintain a fragile hemostatic equilibrium until physiological stressors (trauma, severe infection, tickborne illness, pregnancy) trigger catastrophic acute microvascular thrombosis.
  3. The ADAMTS13 Biomarker Paradox: Identifying severe ADAMTS13 deficiency (<5%) with a negative functional neutralizing inhibitor assay (<0.4 BU) alongside a positive anti-ADAMTS13 IgG ELISA suggests non-neutralizing clearance autoantibodies accelerating enzyme destruction on an inherited substrate.
  4. PLASMIC Risk Stratification Score: A PLASMIC score ≥6 (severe thrombocytopenia <30k, hemolysis, no active cancer/transplant, INR <1.5, creatinine <2.0 mg/dL) predicts severe ADAMTS13 deficiency with high specificity, mandating immediate empiric plasma exchange.
  5. Focal Neurologic Deficits as an Emergency Trigger: The onset of acute transient neurologic deficits (expressive aphasia, pronator drift) in microangiopathic hemolytic anemia signifies cerebral microthrombosis and demands immediate Therapeutic Plasma Exchange (TPE) without waiting for lab results.
  6. Biphasic Relapsing Clinical Course: Self-limited episodes of acute thrombocytopenia occurring years apart (e.g. trauma 3 years prior followed by tickborne infection) are classic for congenital TTP unmasked by episodic environmental triggers.
  7. Distinction between Neutralizing and Clearance Antibodies: Neutralizing autoantibodies inhibit ADAMTS13 catalytic cleavage of vWF (classic acquired TTP), whereas non-neutralizing clearance autoantibodies bind ADAMTS13 to accelerate its clearance from circulation.
  8. Diagnostic Superiority of TPE over Simple Plasma Infusion: In patients with non-neutralizing clearance autoantibodies, simple plasma infusion fails to sustain ADAMTS13 levels because the antibody rapidly clears infused enzyme; active plasmapheresis (TPE) is required to remove clearance antibodies.
  9. Role of Targeted Rituximab Therapy: Administering Rituximab (375 mg/m² weekly x 4 doses) depletes autoreactive B-cell clones producing non-neutralizing anti-ADAMTS13 IgG autoantibodies, restoring baseline enzyme kinetics and preventing early post-TPE relapses.
  10. Modern Prophylaxis with Recombinant ADAMTS13: Recombinant ADAMTS13 (Adzynma) enzyme replacement therapy represents the definitive prophylactic standard for Upshaw-Schulman Syndrome, preventing volume overload and transfusion reactions associated with chronic FFP.
  11. Prophylactic Fresh Frozen Plasma (FFP) Protocols: When recombinant enzyme is unavailable, regular prophylactic FFP infusions (10–15 mL/kg every 8 to 10 weeks without exchange) supply functional ADAMTS13 enzyme to maintain hemostatic baseline.
  12. Distinction from Tickborne Microangiopathies: While tickborne infections (Borrelia burgdorferi, Babesia microti) can induce secondary cytopenias or trigger TTP flares, severe schistocytic MAHA with neurologic deficits and ADAMTS13 <5% confirms underlying TTP.
  13. Cascade Genetic Screening for Relatives: Confirmation of inherited TTP mandates genetic counseling and targeted ADAMTS13 gene mutation screening for first-degree family members to identify asymptomatic carriers at risk of stress-induced TTP.
  14. Avoidance of Platelet Transfusions in TTP: Transfusing exogenous platelets in TTP is strictly contraindicated because circulating ultra-large vWF multimers rapidly aggregate infused platelets, precipitating fatal microvascular thrombosis.
  15. Patient Education & Trigger Action Plan: Patients with Upshaw-Schulman Syndrome must carry emergency medical-alert documentation and follow a strict protocol requiring immediate medical evaluation and ADAMTS13 replacement during acute infections or trauma.